Johnson & Johnson has won FDA approval for a new once-a-day HIV drug, adding to its growing portfolio of treatment options for the condition. Now J&J must find a way to distinguish the drug in an increasingly crowded market that
read moreWith just six weeks to go until the prestigious PharmaTimes Marketer of the Year closes for entry, marketers at all levels of their career are looking forward to taking part in the 25th anniversary celebrations. More: Fly your company's flag
read moreWith new lung cancer data, Roche touted another triumph Thursday for red-hot immuno-oncology drug Tecentriq. But the way some analysts see things, it may actually be a win for its Merck-made nemesis Keytruda. More: Is Roche's latest Tecentriq win really
read moreTakeda says it has late-stage trial results showing the benefit of an investigational subcutaneous formulation of Entyvio to patients with ulcerative colitis. More: Sub-cutaneous form of Entyvio hits PhIII safety, efficacy goals Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals